Medical/Pharmaceuticals

Antengene to Participate in Three Upcoming Investor Conferences in May/June

CICC Healthcare Industry Forum 2022: May 9th to 12th BTIG Virtual China Biotech Day: June 1st Citi's 3rd Pan-Asia Regional Investor Conference 2022: June 8th to June 10th SHANGHAI and HONG KONG, May 6, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading inno...

2022-05-06 08:30 2480

Harbour BioMed Appoints Dr. Alexander A. Zukiwski to its Scientific Advisory Board

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, May 5, 2022 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX:02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics, is pleased to announce the appointment o...

2022-05-06 08:00 1851

World Lupus Federation Global Survey of People Living with Lupus finds 87% Report at Least One Major Organ Affected by the Disease

Survey Findings Released in Advance of World Lupus Day on May 10 WASHINGTON, May 6, 2022 /PRNewswire/ -- In a recent international survey, the World Lupus Federation found that 87% of the survey respondents living with lupus reported that the disease has impacted one or more major organs or organ...

2022-05-06 07:00 2297

Insilico Medicine expands synthetic lethality portfolio with the nomination of a preclinical candidate targeting MAT2A for the treatment of MTAP-deleted cancers

NEW YORK, May 6, 2022 /PRNewswire/ -- Insilico Medicine ("Insilico"), a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, today announced that the company has nominated a preclinical candidate (PCC) targeting methionine adenosyltransferase 2A (MAT2A) from AI-de...

2022-05-06 05:00 2501

Insilico Medicine expands synthetic lethality portfolio with nomination of a preclinical candidate targeting MAT2A for the treatment of MTAP-deleted cancers

NEW YORK, May 5, 2022 /PRNewswire/ -- Insilico Medicine ("Insilico"), a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, today announced that the company has nominated a preclinical candidate (PCC) targeting methionine adenosyltransferase 2A (MAT2A) from AI-de...

2022-05-05 23:00 2548

AHRA and United Imaging launch a new program to develop exceptional leaders.

Announcing AHRA's Transformative Leaders of Choice Program HOUSTON, May 5, 2022 /PRNewswire/ -- AHRA, The Association for Medical Imaging Management, the professional organization representing all levels of management in hospital imaging departments, freestandin...

2022-05-05 22:15 1714

HOYA Vision Care Releases Results of First of its Kind Six-Year MiYOSMART Spectacle Lens Follow-up Clinical Study

Strong evidence shows continued long-term lens effectiveness in slowing myopia progression in children BANGKOK, May 5, 2022 /PRNewswire/ -- HOYA Vision Care, a leader in optical technology innovation, shared the results of asix-year follow-up clinical study on its award winning MiYOSMART spectac...

2022-05-05 22:12 2884

Daewoong Pharmaceutical announced first-quarter 2022 results

- Marked sales of KRW 272.2 billion and operating profit of KRW 26.8 billion - Reported record-high quarterly operating profit, thanks to highly profitable ETC drugs and export growth of Nabota - Expected to see increasing profitability and robust growth due to export expansion of Nabota and the...

2022-05-05 21:00 1722

TIKOMED and IQVIA announce a strategic collaboration for the development of TIKOMED's lead drug platform candidate ILB®

VIKEN, Sweden, May 5, 2022 /PRNewswire/ -- Today, Swedish biopharmaceutical company TikoMed AB and IQVIA announce a key strategic collaboration with the aim to accelerate the development of TikoMed's lead drug platform candidate ILB®, a broad-spectrum small molecule drug candidate with curative p...

2022-05-05 20:40 1420

SOPHiA GENETICS Announces Nomination of Jean-Michel Cosséry to Board of Directors

BOSTON and LAUSANNE, Switzerland, May 5, 2022 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a leader in data-driven medicine, today announced the nomination of Jean-Michel Cosséry to its Board of Directors. The Board of Directors will propose the appointment of Mr. Cosséry as a member of the Bo...

2022-05-05 20:27 1689

Leading HealthTech AI company NuraLogix announces new partnership with LaFiya TeleHealth

TORONTO, May 5, 2022 /PRNewswire/ -- NuraLogix, a leading HealthTech AI company, has announced a new partnership with LaFiya TeleHealth, a Nigerian-based telehealth platform which provides 24/7 virtual healthcare services to residents in remote and rural areas. LaFiya Telehealth provides medical...

2022-05-05 20:15 1718

I-Mab Provides Updates on Status under Holding Foreign Companies Accountable Act

SHANGHAI and GAITHERSBURG, Md., May 5, 2022 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today provided updates on its status under the Holding Foreign...

2022-05-05 20:00 1446

111, Inc. Provides Updates on its Status Under the Holding Foreign Companies Accountable Act

SHANGHAI, May 5, 2022 /PRNewswire/ -- 111 Inc. ( "111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company inChina, today announced that onMay 4th, 2022, the Securities and Exchange Commission (the "SEC") provisionally listed the Company as a "Commission-Identified ...

2022-05-05 17:18 1557

Clinical Trial Approval For ReCOV In The PRC And The Overseas Clinical Trial Progress Of ReCOV

TAIZHOU, China, May 5, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the"Company", together with its subsidiaries, the "Group",Stock code:2179.HK) is pleased to announce that the Company has recently received the clinical trial approval (the "Clinical Trial Approval") for its recombin...

2022-05-05 11:55 2501

Panoramic Atlases of Life Published in Cell Mark Establishment of SpatioTemporal Omics Consortium

STOC launches with more than 80 scientists joining globally, focused on obtaining the greatest scientific benefits fromspatially resolved transcriptomics technology; first studies use BGI-Research's Stereo-seq to produce spatiotemporal cellular maps of mice, Drosophila, zebrafish, and Arabidopsi...

2022-05-05 09:00 3350

Panoramic Atlases of Life Published in Cell Mark Establishment of SpatioTemporal Omics Consortium

STOC launches with more than 80 scientists joining globally, focused on obtaining the greatest scientific benefits fromspatially resolved transcriptomics technology; first studies use BGI-Research's Stereo-seq to produce spatiotemporal cellular maps of mice, Drosophila, zebrafish, and Arabidopsi...

2022-05-05 09:00 1897

First Patient Dosed in Phase II Renal Cancer Theranostics Study

MELBOURNE, Australia and INDIANAPOLIS, May 5, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that a first patient has been dosed in the 'STARLITE 2' Phase II study of the Company's investigational renal cancer therapy, TLX250 (177 Lu-DOTA-girentu...

2022-05-05 05:00 2134

Kintor Pharma Announces First Patient Dosing in Multi-Regional Global Phase II Clinical Trial of ALK-1 Antibody and Nivolumab Combination Therapy for the Treatment of Advanced Hepatocellular Carcinoma

SUZHOU, China, May 4, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma," HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced the first patient dosing inthe United States of its multi-regional pha...

2022-05-04 20:36 2118

Nanoform launches "STARMAP® Online" placing AI-power at the fingertips of medicine developers

HELSINKI, May 4, 2022 /PRNewswire/ -- Nanoform Finland Plc., an innovative nanoparticle medicine-enabling company, today announced that it has launched its sparse-data AI solution (STARMAP® Online) as a secure online portal for direct use by its current and future partners. Since its inception i...

2022-05-04 14:35 1809

Juniper Biologics signs exclusive license agreement with Helsinn for infigratinib (INN) for the emerging markets*

LUGANO, Switzerland, and SINGAPORE, May 4, 2022 /PRNewswire/ -- Juniper Biologics Pte Ltd, a science-led healthcare company focused on researching, developing and commercializing novel therapies, and Helsinn Group, a fully integrated, global biopharma company with a diversified pipeline of innova...

2022-05-04 14:00 2026
1 ... 248249250251252253254 ... 576